BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Newer Drugs May Cut Stroke, Heart Attack Risk


10/19/2005 5:12:57 PM

Patients with high blood pressure taking a mixture of newer drugs may cut their risk of stroke by 25 percent and dangerous heart complications by 15 percent compared with those on older pills, according to a large study released on Tuesday. The advantage is so dramatic that many patients on the older regime of a beta blocker drug and a diuretic should halt their treatment and begin taking the newer combination, which includes Pfizer Inc.'s .drug Norvasc and CV Therapeutics' Aceon, researchers said. The 20,000-person, Pfizer-funded study was halted early, last November, after researchers found the drugs were so much better than conventional treatment with a beta-blocker and a diuretic. Full results were presented at the American College of Cardiology meeting in Orlando, Florida, which ends on March 9. The newer drugs are Norvasc, known generically as amlodipine, a calcium channel blocker and perindopril, an ACE inhibitor, sold by CV Therapeutics and Solvay Pharmaceuticals as Aceon. They were tested in the study against AstraZeneca's atenolol, a beta blocker that has been off patent for several years, and a diuretic pill.

Read at Reuters

Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES